Back to all products

Neuronal TGase (TG6) ELISA

ZediXplore TG6-ELISA IgA and IgG (E003 / E004) are not available any more.
The ZediXclusive TG6-ab ELISA kits E103 and E104 are the revised versions of the ZediXplore TG6-ab ELISA kits E003 and E004

Improvements:
  • No need for background subtraction. Therefore, now you can measure up to 40 sera in duplicates with one kit.
  • The calibrators are adapted, so that the more relevant lower titers are covered. Titers (U/mL) obtained by the new E103/E104 kits can be translated to titers of old kit versions E003/E004 and vice versa!
  • Cutoffs are redefined based on a sera collective of 38 blood donors, equally distributed by sex and age, and a collective of 86 patients with various neurological disorders.


Art. No.
Name
Quantity
Price
E103 ZediXclusive TG6-ab ELISA (IgA)
Neuronal transglutaminase (TG6) ELISA IgA 1 Kit/96 wells
 520 €
E104 ZediXclusive TG6-ab ELISA (IgG)
Neuronal transglutaminase (TG6) ELISA IgG 1 Kit/96 wells
 520 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • Team-Assistenz (w/m/d) in Teilzeit gesucht
    Read more All news
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
    Read more All news
  • imagePreview: Catalogue Editorial 2019
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
    Read more All news
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
    Read more All news
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
    Read more All news
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    Read more All news
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
    Read more All news
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
    Read more All news
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
    Read more All news
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
    Read more All news
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
    Read more All news
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
    Read more All news
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
    Read more All news

Blog  

Events  

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

    All events
  • European Congress on Thrombosis and Haemostasis

    02.10.2019 - 04.10.2019
    Glasgow, United Kingdom

    All events
  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

    All events
  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

    All events